HCP Live (8/14, Derman) reports a study found that “esketamine provided rapid improvement in sleep quality among patients with treatment-resistant depression (TRD).” Investigators “sought to compare the effectiveness of esketamine up to 84 mg/day vs other standard antidepressants in improving sleep quality in patients with TRD.” Researchers found that “insomnia occurs less frequently among people using esketamine than other antidepressants.” They observed that at 6 months, “insomnia levels in patients treated with esketamine reduced significantly; only 1 participant from the esketamine group reported insomnia at this point.” Furthermore, “participants on esketamine experienced significantly improved well-being the next day, with significantly fewer reporting worse well-being, as well as significantly improved mental and physical performance.” The study was published in Pharmaceuticals. (SOURCE: APA Headliens)